BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild‐type RAS

No abstract is available for this paper.

• Publication year

  2014

• Venue

  American journal of hematology/oncology

• Publication date

  2014-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ajh.23652PMID 24446311PMCID PMC4207363
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clonal architecture of chronic myelomonocytic leukemias.

  2013cited by this paper
• Prognostic score including gene mutations in chronic myelomonocytic leukemia.

  2013cited by this paper
• Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes

  2013cited by this paper
• Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.

  2013cited by this paper
• Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia

  2013cited by this paper
• Lys63-linked polyubiquitination of BRAF at lysine 578 is required for BRAF-mediated signaling

  2013cited by this paper
• Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

  2013cited by this paper
• Distinct requirement for an intact dimer interface in wild‐type, V600E and kinase‐dead B‐Raf signalling

  2012cited by this paper
• Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature

  2012cited by this paper
• A landscape of driver mutations in melanoma.

  2012cited by this paper
• LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.

  2012cited by this paper
• Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.

  2012cited by this paper
• Progression of RAS-mutant leukemia during RAF inhibitor treatment.

  2012cited by this paper
• Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management

  2012cited by this paper
• The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development

  2012cited by this paper
• Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.

  2011cited by this paper
• RAS oncogenes: weaving a tumorigenic web

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

  2011cited by this paper
• Cytogenetic risk stratification in chronic myelomonocytic leukemia

  2011cited by this paper
• Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.

  2011cited by this paper
• Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.

  2010cited by this paper
• The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration

  2010cited by this paper
• Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia.

  2010cited by this paper
• RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant

  2010cited by this paper
• BRAF inactivation drives aneuploidy by deregulating CRAF.

  2010cited by this paper
• Application of COLD-PCR for improved detection of KRAS mutations in clinical samples

  2009cited by this paper
• High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

  2009cited by this paper
• Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

  2009cited by this paper
• Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.

  2009influential reference
• Epigenetic-Genetic Interactions in the APC/WNT, RAS/RAF, and P53 Pathways in Colorectal Carcinoma

  2008cited by this paper
• LKB1 modulates lung cancer differentiation and metastasis

  2007cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene

  2007cited by this paper
• Apaf1 in Chronic Myelogenous Leukemia (CML) Progression: Reduced Apaf1 Expression is Correlated with a H179R p53 Mutation During Clinical Blast Crisis

  2007cited by this paper
• Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.

  2006cited by this paper
• Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.

  2006cited by this paper
• Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.

  2005cited by this paper
• Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia

  2005cited by this paper
• Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

  2004cited by this paper
• Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

  2004cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.

  2002cited by this paper
• Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase.

  1998cited by this paper
• A serine/threonine kinase gene defective in Peutz–Jeghers syndrome

  1998cited by this paper
• Chronic myelomonocytic leukemia.

  1990cited by this paper
• Proposals for the classification of the myelodysplastic syndromes

  1982cited by this paper

• Emperipolesis, not hemophagocytosis: chronic myelomonocytic leukemia with neoplasia-associated Rosai–Dorfman disease

  2025cites this paper
• PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML

  2025cites this paper
• BRAF mutation in myeloid neoplasm: incidences and clinical outcomes

  2024cites this paper
• BRAF V600E-Mutant Acute Myeloid Leukemia: A Case Series and Literature Review of a Rare Entity

  2024cites this paper
• scTML: a pan-cancer single-cell landscape of multiple mutation types

  2024cites this paper
• BRAF Mutations in Patients with Myeloid Neoplasms: A Cancer Center Multigene Next-Generation Sequencing Analysis Experience

  2024cites this paper
• Specific blood monocyte distribution in histiocytoses correlates with vascular involvement and disease activity

  2023cites this paper
• Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma.

  2023cites this paper
• Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML

  2022cites this paper
• Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy.

  2022cites this paper
• TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

  2022cites this paper
• Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers

  2021cites this paper
• Chronic myeloid leukemia with insertion-derived BCR–ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis

  2020cites this paper
• Langerhans cell histiocytosis associated with chronic myelomonocytic leukaemia both harbouring the same BRAF V600E mutation: efficacy of vemurafenib

  2020cites this paper
• Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing.

  2020cites this paper
• Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms.

  2019cites this paper
• Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML

  2019cites this paper
• Ocular infiltration as initial presentation of acute monocytic leukaemia transformed from chronic myelomonocytic leukaemia associated with BRAF V600E mutation

  2019cites this paper
• PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm

  2019cites this paper
• Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation

  2019cites this paper
• Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection

  2019cites this paper
• BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers

  2018cites this paper
• Chronic Myelomonocytic Leukemia: Clinical and Pathologic Features

  2018cites this paper
• CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia

  2018cites this paper
• Recent Updates on Chronic Myelomonocytic Leukemia

  2018cites this paper
• Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia

  2018cites this paper
• P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse‐free survival

  2018cites this paper
• Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations

  2018cites this paper
• Myeloid neoplasms with concurrent BCR‐ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm

  2017cites this paper
• Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai–Dorfman disease

  2017cites this paper
• Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis

  2017cites this paper
• Molecular Biology of Leukemias

  2017cites this paper
• The circular RNA of peripheral blood mononuclear cells: Hsa_circ_0005836 as a new diagnostic biomarker and therapeutic target of active pulmonary tuberculosis.

  2017cites this paper
• The Myelodysplastic Syndromes and the Myelodysplastic/Myeloproliferative Neoplasms

  2017cites this paper
• TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis

  2015cites this paper
• Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.

  2015cites this paper
• AWARD NUMBER: W81XWH-12-1-0041 TITLE: Understanding and Targeting Epigenetic Alterations in Acquired Bone Marrow Failure

  2015cites this paper
• Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations

  2014cites this paper